The Effectiveness of Magnesium Sulfate in Treating Severe Trauma-Related Brain Injuries
DOI:
https://doi.org/10.63682/jns.v13i1.9237Keywords:
Traumatic brain injury, magnesium sulfate, neuroprotection, Glasgow Outcome Scale, critical care, secondary brain injury, ICU, trauma managementAbstract
Background: Severe traumatic brain injuries (TBI) inflict a profound and considerable burden on public health systems due to their high mortality rates, as well as the long-term disability associated with them. Even with improvements in critical care, options to mitigate further damage to the brain after injury is sustained remain insufficient. Magnesium sulfate has promising manual neuroprotective characteristics due to its calcium channel blockade mechanism and diminished excitotoxicity effects. To assess the clinical effectiveness of magnesium sulfate in achieving severe trauma brain injury patient survival, neurological outcome, complication reduction in infection, and overall outcomes and survival enhancement.
Methods: This study prospectively considered a sample of 93 patients suffering from severe traumatic brain injuries (TBI) from June 2022 to June 2023. Intravenous magnesium sulfate was given according to the patient's weight and clinical condition, following set protocols. Data was gathered on age-related factors and injury details including the underlying cause, initial GCS (Glasgow Coma Scale) scores, ICU dependency, magnesium concentration during hospitalization, any complications encountered, and GOS (Glasgow Outcome Scale) score upon discharge. The data was analyzed statistically using relevant tests assuming a type I error of p < 0.05.
Results: The majority of patients were male (67.7%) with a mean age of 38.7 years. Road traffic accidents were the most common cause of injury. Good recovery was observed in 54.8% of patients based on the GOS. Serum magnesium levels remained within the therapeutic range in 88.2% of cases. Complications such as hypotension and bradycardia were minimal. Overall survival was 78.5%, with statistically significant improvement in neurological outcomes (p = 0.034).
Conclusion: Magnesium sulfate appears to be a safe and effective adjunctive therapy in the management of severe traumatic brain injuries. Its use was associated with better neurological recovery and lower mortality. Further multicenter randomized trials are recommended to validate these findings and refine treatment protocols.
Downloads
References
Cigel, A., et al., Long term neuroprotective effects of acute single dose MK-801treatment against traumatic brain injury in immature rats. Neuropeptides, 2021. 88: p. 102161.
Williams, A.M., et al., Early treatment with exosomes following traumatic brain injury and hemorrhagic shock in a swine model promotes transcriptional changes associated with neuroprotection. Journal of Trauma and Acute Care Surgery, 2020. 89(3): p. 536-543.
Kerr, N., et al., Neural-respiratory inflammasome axis in traumatic brain injury. Experimental neurology, 2020. 323: p. 113080.
Young, F.G. and D. Nguyen, Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report. Journal of Medical Case Reports, 2020. 14: p. 1-5.
Conner, J., et al., Combatting ischemia reperfusion injury from resuscitative endovascular balloon occlusion of the aorta using adenosine, lidocaine and magnesium: a pilot study. Journal of Trauma and Acute Care Surgery, 2021. 91(6): p. 995-1001.
Petruzella, F. and J.S. Easter, Pediatric emergency medicine literature 2020. The American Journal of Emergency Medicine, 2021. 43: p. 123-133.
Foster, M.A., et al., Mapping the steroid response to major trauma from injury to recovery: a prospective cohort study. The Journal of Clinical Endocrinology & Metabolism, 2020. 105(3): p. 925-937.
Esfahani, H., et al., Ketamine sub-dissociative dose vs. morphine sulfate for acute pain control in patients with isolated limb injuries in the emergency department: a randomized, double-blind, clinical trial. Bulletin of Emergency & Trauma, 2021. 9(2): p. 73.
Omelchenko, A., N.K. Singh, and B.L. Firestein, Current advances in in vitro models of central nervous system trauma. Current opinion in biomedical engineering, 2020. 14: p. 34-41.
Takada, S., et al., Disruption of Midkine gene reduces traumatic brain injury through the modulation of neuroinflammation. Journal of Neuroinflammation, 2020. 17: p. 1-12.
Peck, K.A., et al., Early anticoagulant reversal after trauma: a Western Trauma Association critical decisions algorithm. Journal of Trauma and Acute Care Surgery, 2021. 90(2): p. 331-336.
Kellum, J.A., et al., Acute kidney injury. Nature reviews Disease primers, 2021. 7(1): p. 52.
Rauch, S.A., et al., Neuroendocrine biomarkers of prolonged exposure treatment response in military-related PTSD. Psychoneuroendocrinology, 2020. 119: p. 104749.
Mahumane, G.D., et al., Repositioning N-acetylcysteine (NAC): NAC-loaded electrospun drug delivery scaffolding for potential neural tissue engineering application. Pharmaceutics, 2020. 12(10): p. 934.
Nebie, O., Examining the neuroprotective and neuro-restorative efficacy of heat-treated human platelet pellet lysate in traumatic brain injury models. 2021, Université de Lille; Taipei medical university (Taipei).
Drummond, S., R.S. Ackerman, and A. Somasundaram, Pain assessment and treatment for the trauma and burn patient. Pain Management for Clinicians: A Guide to Assessment and Treatment, 2020: p. 3-30.
Valade, G., et al., Therapeutic potential of mesenchymal stromal cell-derived extracellular vesicles in the prevention of organ injuries induced by traumatic hemorrhagic shock. Frontiers in Immunology, 2021. 12: p. 749659.
Foster, M., et al., Mapping the steroid response to major trauma from injury to recovery. 2020.
Fecher, A., et al., The pathophysiology and management of hemorrhagic shock in the polytrauma patient. Journal of clinical medicine, 2021. 10(20): p. 4793.
Lee, R.P., et al., Neurosurgical emergencies. Neurointensive Care Unit: Clinical Practice and Organization, 2020: p. 195-230.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
